Loading patent…
AssigneeImmvira Biopharmaceuticals Co., Limited
InventorsXiaoqing CHEN, Yuanyuan LIU, Ziwen LIU, Tianyi DENG, Grace Guoying ZHOU
Estimating the term…
Disclosed is a genetically modified oncolytic herpes simplex virus (oHISV) encoding a truncated nonsignaling variant of at least one tumor associated/specific antigen, and at least one chemokine. The expression of the truncated nonsignaling variant and the chemokine is under the control of an immediate-early gene promoter of HSV, and the truncated nonsignaling variant is expressed and presented on a tumor cell surface as a biomarker upon replication of the oHSV in the tumor cell, and the chemokine is expressed and released to induce chemotaxis of an immune cell towards the tumor cell. The genetically modified oHSV can be used in combination with CAR-T, ADC, and/or BiTE therapies.
A genetically modified oncolytic herpes simplex virus (oHSV),
A genetically modified oncolytic herpes simplex virus (oHSV), wherein the genome of the oHSV is incorporated with a polynucleotide encoding a truncated nonsignaling variant of at least one tumor associated/specific antigen, wherein the expression of the truncated nonsignaling variant is under the control of an immediate-early gene promoter of HSV, and wherein the truncated nonsignaling variant is expressed and presented on a tumor cell surface as a biomarker upon replication of the oHSV in the tumor cell.
Dependencies are inferred from the claim text.